Suppression of immune responses in collagen-induced arthritis by a rationally designed CD80-binding peptide agent

Mythily Srinivasan, Rajaraman Eri, Susan L. Zunt, Don John Summerlin, David Brand, Janice S. Blum

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

Objective. The CD80/CD86-CD28/CD152 costimulatory pathways transmit signals for CD4+ T cell activation and suppression and are critically involved in the pathogenesis of rheumatoid arthritis (RA). A significant number of CD4+ T cells and macrophages in the rheumatoid synovium express elevated levels of CD80, increasing the potential for costimulation in trans of naive T cells. To determine the effect of blockade of this costimulatory axis in RA, we designed novel CD80-binding peptides and evaluated their therapeutic potential in collagen-induced arthritis (CIA), an animal model of RA. Methods. The conserved MYPPPY motif of CD152 adopts a polyproline type II (PPII) helical conformation in the CD80-CD152 complex. The pairing preferences of the critical residues at the CD80-CD152 interface and their propensity to form PPII helices were integrated to design peptides with optimum PPII helical content that selectively block CD80-receptor interactions. The clinical efficacy was tested in DBA/1LacJ mice that were administered the CD80 blocking agents, called CD80-binding competitive antagonist peptides (CD80-CAPs), at the time of immunization with bovine type II collagen or 3 weeks after immunization. Results. A single administration of select CD80-CAPs significantly reduced the clinical, radiologic, and histologic disease severity in CIA. Importantly, administration of CD80-CAPs during activated immune response significantly suppressed disease development by reducing mononuclear cell infiltration in the joints and mediating peripheral deletion of activated CD4+ T cells. Conclusion. A rationally designed CD80-binding peptide both prevents and suppresses CIA, suggesting a potential application in RA. Apoptosis of activated CD4+ T cells following in vivo blockade suggests that the effects of CD80-CAPs may be long-lasting.

Original languageEnglish (US)
Pages (from-to)498-508
Number of pages11
JournalArthritis and rheumatism
Volume56
Issue number2
DOIs
StatePublished - Feb 1 2007

Fingerprint

Experimental Arthritis
Rheumatoid Arthritis
T-Lymphocytes
Peptides
Immunization
Inbred DBA Mouse
Collagen Type II
Synovial Membrane
Signal Transduction
Animal Models
Joints
Macrophages
Apoptosis
CD80-CAP
polyproline

All Science Journal Classification (ASJC) codes

  • Immunology and Allergy
  • Rheumatology
  • Immunology
  • Pharmacology (medical)

Cite this

Suppression of immune responses in collagen-induced arthritis by a rationally designed CD80-binding peptide agent. / Srinivasan, Mythily; Eri, Rajaraman; Zunt, Susan L.; Summerlin, Don John; Brand, David; Blum, Janice S.

In: Arthritis and rheumatism, Vol. 56, No. 2, 01.02.2007, p. 498-508.

Research output: Contribution to journalArticle

Srinivasan, Mythily ; Eri, Rajaraman ; Zunt, Susan L. ; Summerlin, Don John ; Brand, David ; Blum, Janice S. / Suppression of immune responses in collagen-induced arthritis by a rationally designed CD80-binding peptide agent. In: Arthritis and rheumatism. 2007 ; Vol. 56, No. 2. pp. 498-508.
@article{b37b7e5a2a3e4ad8b4d59242f56015f3,
title = "Suppression of immune responses in collagen-induced arthritis by a rationally designed CD80-binding peptide agent",
abstract = "Objective. The CD80/CD86-CD28/CD152 costimulatory pathways transmit signals for CD4+ T cell activation and suppression and are critically involved in the pathogenesis of rheumatoid arthritis (RA). A significant number of CD4+ T cells and macrophages in the rheumatoid synovium express elevated levels of CD80, increasing the potential for costimulation in trans of naive T cells. To determine the effect of blockade of this costimulatory axis in RA, we designed novel CD80-binding peptides and evaluated their therapeutic potential in collagen-induced arthritis (CIA), an animal model of RA. Methods. The conserved MYPPPY motif of CD152 adopts a polyproline type II (PPII) helical conformation in the CD80-CD152 complex. The pairing preferences of the critical residues at the CD80-CD152 interface and their propensity to form PPII helices were integrated to design peptides with optimum PPII helical content that selectively block CD80-receptor interactions. The clinical efficacy was tested in DBA/1LacJ mice that were administered the CD80 blocking agents, called CD80-binding competitive antagonist peptides (CD80-CAPs), at the time of immunization with bovine type II collagen or 3 weeks after immunization. Results. A single administration of select CD80-CAPs significantly reduced the clinical, radiologic, and histologic disease severity in CIA. Importantly, administration of CD80-CAPs during activated immune response significantly suppressed disease development by reducing mononuclear cell infiltration in the joints and mediating peripheral deletion of activated CD4+ T cells. Conclusion. A rationally designed CD80-binding peptide both prevents and suppresses CIA, suggesting a potential application in RA. Apoptosis of activated CD4+ T cells following in vivo blockade suggests that the effects of CD80-CAPs may be long-lasting.",
author = "Mythily Srinivasan and Rajaraman Eri and Zunt, {Susan L.} and Summerlin, {Don John} and David Brand and Blum, {Janice S.}",
year = "2007",
month = "2",
day = "1",
doi = "10.1002/art.22324",
language = "English (US)",
volume = "56",
pages = "498--508",
journal = "Arthritis and Rheumatology",
issn = "2326-5191",
publisher = "John Wiley and Sons Ltd",
number = "2",

}

TY - JOUR

T1 - Suppression of immune responses in collagen-induced arthritis by a rationally designed CD80-binding peptide agent

AU - Srinivasan, Mythily

AU - Eri, Rajaraman

AU - Zunt, Susan L.

AU - Summerlin, Don John

AU - Brand, David

AU - Blum, Janice S.

PY - 2007/2/1

Y1 - 2007/2/1

N2 - Objective. The CD80/CD86-CD28/CD152 costimulatory pathways transmit signals for CD4+ T cell activation and suppression and are critically involved in the pathogenesis of rheumatoid arthritis (RA). A significant number of CD4+ T cells and macrophages in the rheumatoid synovium express elevated levels of CD80, increasing the potential for costimulation in trans of naive T cells. To determine the effect of blockade of this costimulatory axis in RA, we designed novel CD80-binding peptides and evaluated their therapeutic potential in collagen-induced arthritis (CIA), an animal model of RA. Methods. The conserved MYPPPY motif of CD152 adopts a polyproline type II (PPII) helical conformation in the CD80-CD152 complex. The pairing preferences of the critical residues at the CD80-CD152 interface and their propensity to form PPII helices were integrated to design peptides with optimum PPII helical content that selectively block CD80-receptor interactions. The clinical efficacy was tested in DBA/1LacJ mice that were administered the CD80 blocking agents, called CD80-binding competitive antagonist peptides (CD80-CAPs), at the time of immunization with bovine type II collagen or 3 weeks after immunization. Results. A single administration of select CD80-CAPs significantly reduced the clinical, radiologic, and histologic disease severity in CIA. Importantly, administration of CD80-CAPs during activated immune response significantly suppressed disease development by reducing mononuclear cell infiltration in the joints and mediating peripheral deletion of activated CD4+ T cells. Conclusion. A rationally designed CD80-binding peptide both prevents and suppresses CIA, suggesting a potential application in RA. Apoptosis of activated CD4+ T cells following in vivo blockade suggests that the effects of CD80-CAPs may be long-lasting.

AB - Objective. The CD80/CD86-CD28/CD152 costimulatory pathways transmit signals for CD4+ T cell activation and suppression and are critically involved in the pathogenesis of rheumatoid arthritis (RA). A significant number of CD4+ T cells and macrophages in the rheumatoid synovium express elevated levels of CD80, increasing the potential for costimulation in trans of naive T cells. To determine the effect of blockade of this costimulatory axis in RA, we designed novel CD80-binding peptides and evaluated their therapeutic potential in collagen-induced arthritis (CIA), an animal model of RA. Methods. The conserved MYPPPY motif of CD152 adopts a polyproline type II (PPII) helical conformation in the CD80-CD152 complex. The pairing preferences of the critical residues at the CD80-CD152 interface and their propensity to form PPII helices were integrated to design peptides with optimum PPII helical content that selectively block CD80-receptor interactions. The clinical efficacy was tested in DBA/1LacJ mice that were administered the CD80 blocking agents, called CD80-binding competitive antagonist peptides (CD80-CAPs), at the time of immunization with bovine type II collagen or 3 weeks after immunization. Results. A single administration of select CD80-CAPs significantly reduced the clinical, radiologic, and histologic disease severity in CIA. Importantly, administration of CD80-CAPs during activated immune response significantly suppressed disease development by reducing mononuclear cell infiltration in the joints and mediating peripheral deletion of activated CD4+ T cells. Conclusion. A rationally designed CD80-binding peptide both prevents and suppresses CIA, suggesting a potential application in RA. Apoptosis of activated CD4+ T cells following in vivo blockade suggests that the effects of CD80-CAPs may be long-lasting.

UR - http://www.scopus.com/inward/record.url?scp=33847070378&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33847070378&partnerID=8YFLogxK

U2 - 10.1002/art.22324

DO - 10.1002/art.22324

M3 - Article

VL - 56

SP - 498

EP - 508

JO - Arthritis and Rheumatology

JF - Arthritis and Rheumatology

SN - 2326-5191

IS - 2

ER -